59193-77-0

Upstream product

• 64-17-5 ethanol 
• 19036-43-2 aminopivalic acid 
• 2843-17-6 3-bromo-2,2-dimethylpropionic acid 
• 1572-98-1 2-cyano-2-methyl-propionic acid ethyl ester 

Downstream Products

• 7486-91-1 3,3-dimethyl-2-azetidinone 
• 19036-43-2 aminopivalic acid 
• 180181-02-6 3-(tert-Butoxycarbonyl)amino-2,2-dimethylpropanoic Acid 
• 150596-66-0 N-[2-(2'-cyanophenyl)-naphthalen-6-ylmethyl]-3-amino-2,2-dimethylpropionic acid ethyl ester 
• 28992-93-0 3-(Tosylamino)pivalinsaeure 
• 1455094-30-0 3-{[1-cyano-4-hydroxy-7-(3-phenylureido)isoquinoline-3-carbonyl]amino}-2,2-dimethylpropionic acid ethyl ester 
• 1455094-26-4 3-{[1-cyano-7-(4-fluorobenzoylamino)-4-hydroxyisoquinoline-3-carbonyl]amino}-2,2-dimethylpropionic acid ethyl ester 
• 1455088-24-0 3-{[1-cyano-7-(2-ethylphenoxy)-4-hydroxyisoquinoline-3-carbonyl]amino}-2,2-dimethylpropionic acid 
• 1455093-12-5 3-{[1-cyano-7-(2-ethylphenoxy)-4-hydroxyisoquinoline-3-carbonyl]amino}-2,2-dimethylpropionic acid ethyl ester 
• 1455088-19-3 3-{[1-cyano-4-hydroxy-7-(2-methoxyphenoxy)isoquinoline-3-carbonyl]amino}-2,2-dimethylpropionic acid 
• 1455093-08-9 3-{[1-cyano-4-hydroxy-7-(2-methoxyphenoxy)isoquinoline-3-carbonyl]amino}-2,2-dimethylpropionic acid ethyl ester 
• 1455094-69-5 3-[(4-hydroxy-7-phenoxyisoquinoline-3-carbonyl)amino]-2,2-dimethylpropionic acid ethyl ester 
• 1455087-82-7 3-[(1-cyano-4-hydroxy-7-p-tolyloxyisoquinoline-3-carbonyl)amino]-2,2-dimethylpropionic acid 
• 1455092-60-0 3-[(1-cyano-4-hydroxy-7-p-tolyloxyisoquinoline-3-carbonyl)amino]-2,2-dimethylpropionic acid ethyl ester 

Relevant academic research and scientific papers

Pd(II)-Catalyzed Direct ?-C(sp3)-H Arylation between Free β2-Amino Esters and β3-Amino Esters and Aryl Iodides Using a Catalytic Transient Directing Group

Pd(II)-catalyzed direct ?-C(sp3)-H arylation coupling with free β2-amino esters and β3-amino esters using a commercially available catalytic transient directing group has been developed. This approach features high efficiency, broad substrate tolerance, easily accessible starting materials, and mild reaction conditions.

SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS

Compounds having Formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK3 modulation. All the variables defined herein.

USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS

The present invention relates to arylthiazine compounds, metabolites, N-oxides, amides, esters,pharmaceutically acceptable salts, hydrates and solvates thereof and their use as cytoprotectants in the treatment or prophylaxis of diseases or states, either acute or chronic, involving aberrant cellular lipid peroxidation in the central nervous system or in the periphery of the body. The present invention also relates to a method for their preparation and to pharmaceutical composition comprising as an active ingredient one or more of the aforementioned compounds.

4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS

The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.

BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS

Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SlP receptors.

TASK CHANNEL ANTAGONISTS

This invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK-3, and disorders

TASK CHANNEL ANTAGONISTS

This invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK-3, and disorders

Synthesis of sterically hindered 3,5,5-trimethyl 2,6-dioxo tetrahydro pyrimidine as HCV protease inhibitors

An efficient route for the synthesis of sterically hindered substituted and unsubstituted 2,6-dioxo tetrahydropyrimidines from amine 1 is described. These analogs are active against HCV NS3 serine protease. The biological data for some of the representati

POLO-LIKE KINASE INHIBITORS

Compounds of the following formula are provided for use with kinases, wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful

Structural modification of the P2′ position of 2,7-dialkyl- substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: The discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets

Due to its function in the rate limiting initial step of the renin-angiotensin system, renin is a particularly promising target for drugs designed to control hypertension, a growing risk to health worldwide. Despite vast efforts over more than two decades